ACHL Achilles Therapeutics
- 0.760
- -0.014-1.86%
- 0.760
- 0.0000.00%
Achilles Therapeutics News
Achilles Therapeutics Price Target Cut to $6.00/Share From $11.00 by Chardan Capital
Achilles Therapeutics Price Target Cut to $6.00/Share From $11.00 by Chardan Capital
Achilles Therapeutics Is Maintained at Buy by Chardan Capital
Achilles Therapeutics Is Maintained at Buy by Chardan Capital
Achilles Therapeutics Cut to Neutral From Overweight by Piper Sandler
Achilles Therapeutics Cut to Neutral From Overweight by Piper Sandler
Express News | Piper Sandler Downgrades Achilles Therapeutics to Neutral, Lowers Price Target to $2
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of STAAR Surgical Company (NASDAQ:STAA) rose sharply during Thursday's session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%
BRNS, UPC and KWE Among Mid-day Movers
Achilles Therapeutics GAAP EPS of -$0.46 Misses by $0.32
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P
ARCA Biopharma, Achilles Therapeutics, MSP Recovery Among Healthcare Movers
EC, ABAT and BORR Among Pre-market Losers
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Thursday's pre-market session. The market value of their outstanding shares is at $800.0 million. Candel Therapeutics (NASDAQ
Express News | Achilles Therapeutics Shares Are Trading Lower After the Company Reported Q4 Financial Results. The Company Announced Interim Phase I/IIa Data on the Use of Clonal Neoantigen Reactive T Cells From the CHIRON Study in Advanced Unresectable or Metastatic No
Express News | Achilles Therapeutics Q4 EPS $(0.46) May Not Be Comparable To $(0.14) Estimate, Cash Position Of $131.5M Supports Operations Through 2025
Express News | Achilles Therapeutics Provides Interim Phase 1/2a Update on Clonal Neoantigen Reactive T Cells In Advanced NSCLC And Melanoma Including First Patients Dosed With Enhanced Host Conditioning
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
Achilles Therapeutics Announces Publication of Nature Cancer 'Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction
LONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid
Achilles Therapeutics Cut to Underperform From Buy by B of A Securities
Achilles Therapeutics Cut to Underperform From Buy by B of A Securities
B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5
B of A Securities analyst Tazeen Ahmad downgrades Achilles Therapeutics (NASDAQ:ACHL) from Buy to Underperform and lowers the price target from $7 to $0.5.
Achilles Therapeutics Cash And Cash Equivalents As Of Sept. 30 Were $140.1M
Achilles Therapeutics Cash And Cash Equivalents As Of Sept. 30 Were $140.1M
Analysis
Price Target
No Data
